Cohort of Peripheral T Cell Lymphoma

Sponsor
Korea Cancer Center Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT02364466
Collaborator
Samsung Medical Center (Other), Asan Medical Center (Other), Keimyung University Dongsan Medical Center (Other), Kosin University Gospel Hospital (Other), Dankook University (Other), Soonchunhyang University Hospital (Other), Ajou University School of Medicine (Other), Yeungnam University Hospital (Other), Ulsan University Hospital (Other), Inje University (Other), Chung-Ang University Hosptial, Chung-Ang University College of Medicine (Other), Hallym University Medical Center (Other), Hanyang University Seoul Hospital (Other), Seoul National University Hospital (Other), Pusan National University Hospital (Other), National Health Insurance Service Ilsan Hospital (Other), Hanyang University (Other)
200
18
59
11.1
0.2

Study Details

Study Description

Brief Summary

Prospective, observational cohort study of peripheral T cell lymphoma. Purpose is to investigate the complication including febrile neutropenia in the era of pegylated G-CSF prophylaxis.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Prospective evaluation of frequencies of febrile neutropenia or infectious complications in a homogeneous population of patients with peripheral T cell lymphoma

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    200 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Multicenter Prospective Cohort Study of Peripheral T Cell Lymphoma
    Study Start Date :
    Jan 1, 2015
    Anticipated Primary Completion Date :
    Dec 1, 2019
    Anticipated Study Completion Date :
    Dec 1, 2019

    Outcome Measures

    Primary Outcome Measures

    1. Febrile neutropenia [2 years after the last enrollment]

      Incidence and severity of febrile neutropenia

    Secondary Outcome Measures

    1. Infectious complication [2 years after the last enrollment]

      incidence, severity, microbiology of infection

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    19 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Treatment naive peripheral T cell lymphoma
    Subtypes are as followings:

    Anaplastic large cell lymphoma angioimmunoblastic T cell lymphoma Peripheral T cell lymphoma-NOS Enteropathy-associated T cell lymphoma Hepatosplenic T-cell lymphoma Subcutaneous panniculitis-like T-cell lymphoma Primary cutaneous gamma-delta T-cell lymphoma Primary cutaneous CD8+ aggressive epidermotropic lymphoma

    1. Scheduled to receive chemotherapy of curative intent

    2. 19 years old or over

    3. Expected survival is more than 6 months

    4. Informed consent

    Exclusion Criteria:
    1. Other histology than those described above
    • Extranodal NK/T cell lymphoma

    • Other than peripheral T cell lymphoma

    1. Other combined malignancy

    2. Previous history of chemotherapy or radiation therapy

    3. No informed consent

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Dankook University Hospital Cheonan Korea, Republic of
    2 Keimyung University Dongsan Hospital Daegu Korea, Republic of
    3 Yeungnam University Hospital Daegu Korea, Republic of
    4 Hanyang University Guri Hospital Guri Korea, Republic of
    5 Inje University Ilsan Paik Hospital Ilsan Korea, Republic of
    6 National Health and Insurance Service Ilsan Hospital Ilsan Korea, Republic of
    7 Kosin Universithy Gospel Hospital Pusan Korea, Republic of
    8 Pusan National University Hospital Pusan Korea, Republic of
    9 Korea Cancer Center Hospital Seoul Korea, Republic of 139-706
    10 Asan Medical Center Seoul Korea, Republic of
    11 Choong Ang University Hospital Seoul Korea, Republic of
    12 Hallym University Hospital Seoul Korea, Republic of
    13 Hanyang University Hospital Seoul Korea, Republic of
    14 Samsung Medical Center Seoul Korea, Republic of
    15 Seoul National University Hospital Seoul Korea, Republic of
    16 Soonchunhyang University Hospital Seoul Korea, Republic of
    17 Ajou University Hospital Suwon Korea, Republic of
    18 Ulsan University Hospital Ulsan Korea, Republic of

    Sponsors and Collaborators

    • Korea Cancer Center Hospital
    • Samsung Medical Center
    • Asan Medical Center
    • Keimyung University Dongsan Medical Center
    • Kosin University Gospel Hospital
    • Dankook University
    • Soonchunhyang University Hospital
    • Ajou University School of Medicine
    • Yeungnam University Hospital
    • Ulsan University Hospital
    • Inje University
    • Chung-Ang University Hosptial, Chung-Ang University College of Medicine
    • Hallym University Medical Center
    • Hanyang University Seoul Hospital
    • Seoul National University Hospital
    • Pusan National University Hospital
    • National Health Insurance Service Ilsan Hospital
    • Hanyang University

    Investigators

    • Principal Investigator: Won Seog Kim, M.D., Ph.D., Samsung Medical Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Sujin Kang, CRA, Korea Cancer Center Hospital
    ClinicalTrials.gov Identifier:
    NCT02364466
    Other Study ID Numbers:
    • Giraffe-T
    First Posted:
    Feb 18, 2015
    Last Update Posted:
    Feb 18, 2015
    Last Verified:
    Feb 1, 2015

    Study Results

    No Results Posted as of Feb 18, 2015